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Abstract The myogenic b-HLH transcription factor MyoD
activates expression of muscle-specific genes and autoregulates
positively its own expression. Various factors such as growth
factors and oncogene products repress transcriptional activity of
MyoD. The c-mos proto-oncogene product, Mos, is a serine/
threonine kinase that can activate myogenic differentiation by
specific phosphorylation of MyoD which favors heterodimeriza-
tion of MyoD and E12 proteins. Here we show that over-
expression of Mos enhances the expression level of MyoD
protein in myoblasts although phosphorylation of MyoD by Mos
does not modify its stability but promotes transcriptional
transactivation of the MyoD promoter linked to the luciferase
reporter gene. Moreover, co-expression of MyoD with Moswt but
not with the kinase-inactive MosKM greatly enhances expression
of endogenous MyoD protein and the DNA binding activity of
MyoD/E12 heterodimers in 10T1/2 cells. Our data suggest that
Mos increases the ability of MyoD to transactivate both muscle-
specific genes and its own promoter and could therefore
participate in the positive autoregulation loop of MyoD and
muscle differentiation.
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1. Introduction
During myogenesis the transcription of muscle-speci¢c
genes is dependent on a family of muscle-speci¢c factors
which includes MyoD [1,2], myogenin, [3,4], Myf5 [5],
MRF4 [6], known as herculin in mouse [7] and Myf6 in hu-
man [8]. These proteins share a basic helix-loop-helix domain
(b-HLH), which is also common to ubiquitous transcription
factors such as E12 or E47 [9,10] and the HEB gene products
[11] with which myogenic factors mediate dimerization and
binding to a DNA consensus sequence known as a E-box
(CANNTG) [12]. In addition to activation of muscle-speci¢c
genes, some members of the MyoD family also activate their
own transcription and are able to transactivate expression of
other family members [13]. Two proximal E-boxes in the
MyoD promoter were identi¢ed as targets of MyoD binding
as well as autoregulation of MyoD gene expression [14]. It
was postulated that the autoregulatory interactions amplify
the expression of these factors above a threshold for activa-
tion of the muscle di¡erentiation program and stabilization of
the myogenic phenotype. Myogenesis is inhibited by some
mitogens [15] and overexpression of oncogenes and/or pro-
to-oncogenes [16,17]. Myogenic b-HLH proteins are sensitive
to growth factors and oncogene products which can silence
their activities and inhibit myogenic di¡erentiation [18]. Inac-
tivation of the myogenic b-HLH proteins is associated with a
loss of their ability to heterodimerize and to bind DNA [19^
22] and/or of their transcriptional activity [23]. We previously
showed that the c-mos proto-oncogene product, serine/threo-
nine kinase Mos, is up-regulated during skeletal muscle devel-
opment [24,25]. Its expression was originally described as
being restricted to male and female germ cells [26]. In mam-
malian gonad tissues Mos appears to play an important role
in maturation of male and female germinal cells [27^29]. How-
ever, various other somatic cell lineages and tissues express
signi¢cant amounts of Mos products [30^32]. Accumulation
of Mos during skeletal muscle development suggested a par-
ticular function(s) of Mos in this tissue [33]. Indeed, ectopic
expression of Mos activated muscle di¡erentiation while the
inhibition of endogenous Mos expression by antisense RNA
resulted in reversible blockage of myogenesis [33], suggesting
that Mos may interact with myogenic b-HLH proteins. Thus,
unphosphorylated MyoD but not its E12 partner physically
interacts with Mos [34]. Mutational analysis of the protein
reveals a highly conserved region in Mos proteins which
shares sequence homologies with the ubiquitous E12/E47 pro-
teins and associates with the helix 2 domain of MyoD. Phos-
phorylation of the COOH domain of MyoD by Mos inhibits
the DNA binding activity of MyoD homodimers but pro-
motes the formation and DNA binding activity of MyoD-
E12 heterodimers [35]. As the MyoD promoter contains two
E-boxes identi¢ed as targets of MyoD binding and autoregu-
lation of MyoD gene expression, we investigated if Mos could
enhance the transcriptional activity of MyoD on its own pro-
moter as it does on muscle gene promoters. We found that
ectopic expression of Mos causes a increase in the accumula-
tion of MyoD gene products in proliferating C2C12 myo-
blasts and MyoD-expressing 10T1/2 cells. Neither Moswt
nor the kinase-inactive MosKM modi¢es the stability of
MyoD protein. On the other hand, Moswt but not the kin-
ase-inactive MosKM increases the levels of DNA binding and
transcriptional activities of MyoD on its own promoter. Thus
these data indicate that Mos favors the capacity of MyoD to
up-regulate its own expression and promotes the levels of
MyoD products. These results suggest that Mos participates
in the positive autoregulation of MyoD and thus in activation
of muscle di¡erentiation.
2. Materials and methods
2.1. Cell cultures, DNA transfections and luciferase assays
The mouse skeletal muscle cell line C2C12 and the ¢broblast cell
line 10T1/2 were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 20% and 15% fetal calf serum respec-
tively. To obtain G418-resistant colonies, C2C12 cells were stably
transfected by the calcium phosphate procedure with 1 Wg of super-
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coiled pSV2-neo plasmid and 10^15 Wg of the expression vectors
pCMV, pCMV-Moswt or pCMV-mosvNH2 as described previously
[36]. 10T1/2 cells were transfected using polyethyleneimine (PEI, Sig-
ma) essentially as described [37]. The total amount of DNA used for
each plate was normalized with the respective empty expression ve-
hicle. Forty-eight hours after transfection, cells were harvested and
luciferase activity determined on aliquots of cell extracts containing
equivalent amounts of proteins with a luminometer (Lumat LB 9507-
DLA, Berthold). Five hundred nanograms of the plasmid pCH110
(Pharmacia) was included in the assays as an internal control for
transfection e⁄ciency. Experiments were performed in triplicate and
repeated at least twice.
2.2. Plasmid constructions
To create pCMV-Mos, the BamHI restriction fragment of pRSET-
Mos was subcloned into pcDNA3 (Invitrogen) under the control of
the cytomegalovirus (CMV) promoter [34]. Expression vectors
pEMSV-E12 and pEMSV-MyoD have been previously described
[1,12]. Expression vectors pCMVHA-MyoD, pCMVHA-MosWT and
pCMVHA-MosKM were generated by cloning the hemagglutinin (HA)
epitope tag in triplicate at the amino-terminus of cDNA inserts in
pcDNA3. Expression vectors pEMSV-Moswt and pEMSV-MosKM
were generated after excision of the BamHI inserts from pGEX2T-
Moswt and pGEX2T-MosKM constructs previously described [34]. In-
serts were ¢lled in with Klenow DNA polymerase and inserted in
pEMSV at the ¢lled in EcoRI site. Expression vector pCMV-
MosvNH2 was created by inserting a NruI-XbaI fragment encoding
aa 141^339 of the Moswt protein into the SmaI-XbaI sites of pcDNA3
vector. The MyoD promoter fragment HindIII-BsmI [14] was ¢lled in
with Klenow DNA polymerase and cloned into the SmaI site of
pGL3-Luc plasmid harboring the ¢re£y luciferase reporter gene
(Luc) (Promega).
2.3. RNA analysis
For Northern blot analyses, total RNA was isolated by the guani-
dinium isothiocyanate procedure. Hybridization conditions were as
previously described [33]. Randomly primed DNA insert probes
used in hybridizations were for MyoD a 1.8 kb EcoRI fragment of
the mouse MyoD cDNA clone pEM-MyoD [1] and for Gapdh a 1300
bp PstI fragment of the rat glyceraldehyde 3-phosphate dehydrogen-
ase cDNA clone pRGAPDH 13 [38].
2.4. SDS-PAGE immunoblotting
Cells were lysed and total proteins solubilized in RIPA bu¡er con-
taining 10 mM EGTA and processed as previously described [24].
After electrophoretic transfer of proteins onto nitrocellulose mem-
branes, immunodetection was performed with the 12CA5 monoclonal
antibody (dilution: 1/1000, Boehringer) or the MyoD antibody (dilu-
tion: 1/1000, Santa Cruz). After exposure to the secondary antibody,
horseradish peroxidase-linked sheep anti-rabbit or anti-mouse immu-
noglobulin G (Sigma), antigen-antibody complexes were revealed by
the chemoluminescence system (ECL, Amersham). Exposure was per-
formed with Agfa Curix RP2 ¢lms and intensifying screens.
2.5. Electrophoretic mobility shift assay (EMSA)
MyoD DNA binding activity in presence or in absence of co-trans-
fected Moswt and MosKM was determined as described [39]. Twenty
micrograms of whole-cell extract were diluted to a ¢nal volume of 20
Wl in a reaction mixture containing 80 mM NaCl, 10 mM Tris-HCl,
pH 7.4, 5 mM MgCl2, 1 mM dithiothreitol, 5% glycerol, 0.05% NP40,
1 Wg/ml poly(dI-dC), 500 ng of bovine serum albumin and incubated
with 0.1^0.3 ng of 32P-labeled E-box probe (5P-AGCTTCCAA-
CACCTGCTGCAAGCT-3P) derived from the creatine kinase gene
promoter [39]. After a 15 min incubation at 25‡C, antibodies were
added for an additional 15 min incubation, at that time 5 Wl of 0.005%
bromophenol blue/xylene cyanol was added and the binding reactions
analyzed on 4% (w/v) native polyacrylamide gels at 120 V for 2.5 h at
room temperature.
3. Results and discussion
3.1. Stable overexpression of Mos induces increasing expression
of MyoD protein in C2C12 transfectants
Proliferating C2C12 myoblasts were stably transfected with
the neomycin resistance and CMV-Mos constructs. G418-re-
sistant colonies were selected and serially passaged. Transfec-
tants displayed both the normal phenotype and a capacity to
carry out the myogenic program of the parental C2C12 line.
When analyzed by Western blot during exponential growth
and compared to C2C12 control cells (which were transfected
with the empty vehicle), transfectants carrying the moswt gene
displayed variable amounts of MyoD and Mosrat proteins
(Fig. 1A). However, at the same stages of growth, the levels
of MyoD and Mos proteins were found to be higher in C2-
Moswt transfectants than in control cells (Fig. 1B). These
results reveal an increase in the level of MyoD protein expres-
sion when Mos is stably transfected in C2C12 myoblasts. In
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Fig. 1. Protein expression in Mos-transfected myoblasts C2C12. A:
C2C12 cells were stably transfected with the empty vector (control),
the complete coding c-mosrat cDNA (C2-Moswt : clones C1^D2) or
(C) with MosvNH2 (C2-MosvNH2, clones A1^A6), a Mos mutant
with the NH2 domain deleted and maintained in DMEM supple-
mented with 20% FCS for 48 h. 50 Wg of total cell extract was used
for quantitative immunoblots probed with either the a⁄nity-puri¢ed
polyclonal anti-MyoD or the a⁄nity-puri¢ed anti-Emos2 antibody
[24] and developed using enhanced chemiluminescence detection. B,
D: The signals were quantitated with a gel scan (Pharmacia).
Fig. 2. MyoD mRNA expression in Mos-transfected myoblasts
C2C12. Total RNA was prepared from stable transfectants as de-
scribed in Fig. 1. 15 Wg of each RNA sample was run on a 1%
agarose-formaldehyde-MOPS gel, transferred to nitrocellulose ¢lter
and hybrized with a mouse MyoD probe. For MyoD, exposure
time was 6 h. The blots were stripped and reprobed with a rat
Gapdh probe and it was con¢rmed that approximately equal
amounts of RNA were loaded. Exposure time was 18 h.
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contrast, the level of MyoD protein expression was not af-
fected when an inactive Mos protein with the NH2 domain
deleted is stably expressed at high levels in the same cells (C2-
MosvNH2 transfectants) (Fig. 1C,D). Several hypotheses
could explain these results : (I) Mos could enhance the stabil-
ity of MyoD protein; (II) Mos acts at the transcriptional level
to increase expression of MyoD gene; (III) Mos could act
positively on the stability of MyoD mRNA.
3.2. Mos does not modify the stability of MyoD
To elucidate the mechanism by which the level of co-ex-
pressed MyoD is augmented by Mos, we tested whether
Mos a¡ected transcription or translation of the co-transfected
MyoD. We ¢rst examined the e¡ect of Mos expression on the
stability of co-expressed MyoD in 10T1/2 cells. The metabolic
stability of MyoD was investigated by a pulse-chase experi-
ment. Immunoprecipitation analyses with a MyoD-speci¢c
polyclonal antiserum revealed that MyoD was unstable with
a half-life of 50^60 min, in good agreement with its previously
reported half-life of 30^60 min [13]. Surprisingly, MyoD when
co-expressed with Moswt or kinase-inactive MosKM showed a
half-life very similar to that observed for MyoD alone (data
not shown). This result suggests that the much higher level of
co-expressed MyoD compared to that of the singly expressed
MyoD was not due to its metabolic stabilization by Mos ex-
pression. To determine whether Moswt protein can activate
expression of the MyoD gene, we analyzed the expression of
endogenous MyoD mRNA in C2C12 myoblasts that were
either transfected by the empty vehicle (control), the Moswt
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Fig. 4. Mos co-expressed with MyoD activates expression of the endogenous MyoD protein. 10T1/2 cells were co-transfected with 0.5 Wg of
pEMSV-E12 (lanes 1^14), 0.2, 0.5 and 1 Wg of pCMVHA-MosWT (lanes 2^4 and 9^11) or pCMVHA-MosKM (lanes 5^7 and 12^14) alone or in
combination with 0.5 Wg of pCMVHa-MyoD (lanes 8^14). Forty-eight hours following transfection, cells maintained in DMEM supplemented
with 15% FCS were harvested and Western blot analysis was performed. A: Ten micrograms of whole cell extracts was solubilized in SDS
loading bu¡er. After SDS-PAGE, HA-tagged proteins were detected by immunoblotting with the 12CA5 monoclonal antibody. B: Fifty micro-
grams of the same whole extracts was used for SDS-PAGE. Proteins were detected by immunoblotting with the a⁄nity-puri¢ed polyclonal
anti-MyoD antibody.
Fig. 3. Mos enhances MyoD transcriptional transactivation of its
own promoter. 10T1/2 cells were co-transfected with 0.5 Wg of a
plasmid containing the HindIII/BspMI fragment of the mouse
MyoD promoter cloned upstream of the luciferase reporter gene,
0.5 Wg of pEMSV-E12, 0.5 Wg of pCMVHa-MyoD (lane 2) together
with pCMVHA-MosWT (lanes 3^5) or pCMVHA-MosKM (lanes 6^
8). Forty-eight hours following transfection, cells maintained in
DMEM supplemented with 15% FCS were harvested and luciferase
activity was assayed in aliquots equivalent to 10 Wg of whole cell ex-
tracts. Di¡erences in transfection e⁄ciencies were corrected based
upon the level of L-galactosidase activity from the co-transfected
pCH110 plasmid. Each bar represents the average of at least three
independent tranfections.
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expression vector (C2-Moswt) and/or the truncated Mos ex-
pression plasmid (C2-MosvNH2). Fig. 2 shows that expres-
sion of MyoD mRNA in stably transfected cells di¡ered sig-
ni¢cantly between co-expressed Moswt and the truncated
MosvNH2 mutant. Densitometric analysis of MyoD hybrid-
ization bands versus those of Gapdh, a housekeeping gene,
showed that the C2-Moswt transfectants expressed higher
quantities of MyoD mRNA than control C2C12 or C2-
MosvNH2 transfectants. These results suggest that Moswt
a¡ects an event at the transcriptional and/or post-transcrip-
tional level of MyoD.
3.3. Mos enhances MyoD expression at the transcriptional level
Phosphorylation of MyoD by Moswt inhibits the DNA
binding activity of MyoD homodimers, favors the binding
of MyoD-E12 heterodimers and promotes MyoD transcrip-
tional transactivation of the muscle creatine kinase promoter-
enhancer [34]. We wondered if Mos could also enhance MyoD
transcriptional transactivation of its own promoter which
contains two proximal E-boxes known to be the targets of
its autoregulation loop [14]. 10T1/2 cells were transfected
with HA epitope-tagged MyoD and/or together with Moswt
and/or the kinase-inactive MosKM expression vector and a
luciferase reporter gene driven by the HindIII/BspMI frag-
ment of the mouse MyoD promoter. As previously shown
[14], in 10T1/2 cells, MyoD promoter is poorly activated by
MyoD alone (Fig. 3, lane 2). On the other hand, when MyoD
is co-expressed with Moswt, transactivation of the MyoD pro-
moter was enhanced in a dose-dependent manner by Moswt
(Fig. 3, lanes 3^5). At the highest level of Moswt tested, we
observed a 6^8-fold increase in the expression of luciferase
activity. In contrast, MosKM expression stimulated the
MyoD promoter very poorly (Fig. 3, lanes 6^8). Finally, tran-
scriptional stimulation was not observed in the presence of
Moswt or E12 alone (Fig. 3, lanes 9 and 10). These results
show that Moswt strongly enhances MyoD expression at the
transcriptional level suggesting that Mos is not only able to
increase the transcriptional activity of MyoD on muscular
gene expression but is also able to enhance the capacity of
MyoD to activate its own expression.
3.4. Co-expression of Mos and MyoD in 10T1/2 cells activates
expression of endogenous MyoD protein
Stable ectopic expression of MyoD cDNA in 10T1/2 cells
led to the endogenous expression of MyoD [13]. As Mos has
the capacity to enhance transcriptional activity of MyoD on
its own promoter, we decided to verify the e¡ects of co-ex-
pressed Mos and MyoD on the expression of endogenous
MyoD in 10T1/2 cells. Protein lysates identical to those
used in the luciferase assays were analyzed by two Western
blot experiments (Fig. 4A,B). Total cellular proteins were
probed with the monoclonal antibody 12CA5 directed against
HA-tagged MyoD and Mos proteins. The results showed that
HA-MyoD is strongly expressed (Fig. 4, lanes 8^14) and that
increasing amounts of HA-Moswt (lanes 2^4 and 9^11) and
HA-MosKM (Fig. 4A, lanes 5^7 and 12^14) expression vectors
are well correlated with the increasing amounts of correspond-
ing tagged proteins. Moreover, as the exogenous MyoD is
linked to a triplicate HA epitope, its molecular weight on
SDS polyacrylamide gel is increased to 48 kDa instead of
43 kDa, the molecular weight of endogenous MyoD. This
allowed us to distinguish between the exogenous and the en-
dogenous forms of MyoD proteins as observed on a second
Western blot probed with a MyoD polyclonal antibody. Fig.
4B shows that when Moswt or MosKM are expressed alone in
10T1/2 cells, no expression of endogenous MyoD is observed
(Fig. 4A, lanes 2^7). This result con¢rms that Mos alone does
not activate MyoD expression. When HA-MyoD is singly ex-
pressed in these cells, we detect a small expression of endog-
enous MyoD (Fig. 4B, lane 8). On the other hand, when HA-
MyoD is co-expressed with increasing amounts of HA-Moswt
expression vector, expression of endogenous MyoD protein is
enhanced in a dose-dependent manner by Moswt (Fig. 4B,
lanes 9^11). In contrast, the kinase-inactive HA-MosKM had
no e¡ect on the expression of endogenous MyoD protein.
Expression of endogenous MyoD is una¡ected and is identical
to that observed with HA-MyoD transfected alone (Fig. 4B,
lanes 12^14). Taken together, these results demonstrate that
Mos increases the transcriptional activity of MyoD on its own
promoter and increases the potentiality of MyoD to activate
the expression of endogenous MyoD protein.
3.5. Mos activates MyoD DNA binding activity in 10T1/2 cells
To elucidate the mechanism by which the transcriptional
activity of co-expressed MyoD is augmented by Mos, we ex-
amined the DNA binding activity of MyoD when expressed
alone or in combination with Mos in 10T1/2 cells. Total pro-
tein extracts from transfected 10T1/2 cells were analyzed by
Western blots with results similar to those shown in Fig. 4.
Aliquots of total proteins were used in EMSA experiments
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Fig. 5. The DNA binding activity of MyoD is increased in 10T1/2
cells when co-transfected with Mos. 10T1/2 cells were transiently
transfected with 0.5 Wg of pEMSV-E12 (lanes 1^13), 0.5 Wg of
pCMV-HA-MyoD (lanes 5^13), 1 Wg of pCMV-HA-MosWT (lanes
2^4 and 8^10) and 1 Wg of pCMV-HA-MosKM (lanes 11^13).
Twenty micrograms of whole extracts was incubated with a 32P-la-
beled E-box probe. HA antibody (anti HA) or E12 antibody (anti
E12) was added as indicated, and the binding mixtures were sepa-
rated by non-denaturing PAGE. MyoD/E12 complexes are indicated
by an arrow. The extra band in lane 8 which migrates at the same
level as the band supershifted by anti-E12 antibody (lane 7) is prob-
ably an artifact. In long running gels, its migration is slightly faster
than the supershifted band observed with anti-E12 antibody and es-
pecially this retarded band is not currently observed.
B. Benayoun et al./FEBS Letters 437 (1998) 39^4342
with a 32P-labeled MEF1 oligonucleotide. As expected, Mos
does not bind to the E-box DNA probe (Fig. 5, lanes 2^5).
Addition of anti-HA antibody in the binding mixture did not
modify the non-speci¢c protein-DNA complexes observed in
all lanes. When MyoD is expressed ectopically in 10T1/2 cells,
we detected a speci¢c DNA binding complex constituted of
MyoD/E12 heterodimers. When supershift experiments were
performed with antibodies directed against HA epitope or E12
protein, both of these antibodies speci¢cally supershifted this
complex (lanes 5^7). Co-expression of Moswt with MyoD in-
duced an important increase in the retarded bands corre-
sponding to the DNA binding activity of MyoD/E12 hetero-
dimers (compare lanes 5 and 8). Quantitation of the speci¢c
retarded bands showed a 3^5-fold increase in their intensity.
In contrast, the kinase-inactive MosKM did not signi¢cantly
a¡ect the DNA binding activity of MyoD/E12 complexes
(compare lanes 5 and 11). These data show that Mos kinase
increases DNA binding activity of MyoD/E12 heterodimers in
10T1/2 cells.
In conclusion, together these data demonstrate that Mos
can promote the formation of active MyoD/E12 heterodimers
and increase the ability of MyoD to transactivate both
muscle-speci¢c genes [34] and its own promoter and could
therefore participate in the positive autoregulation loop of
MyoD and muscle di¡erentiation. Given that the four b-
HLH muscle factors identi¢ed thus far form a family of nu-
clear phosphoproteins themselves related to a larger family of
regulatory factors, it is tempting to assume that Mos could
play a part in their activation (Benayoun et al., submitted).
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